What was recalled
The U.S. Food and Drug Administration (FDA) has issued a recall for a specific pharmaceutical product manufactured by Chiesi USA, Inc., with distribution managed from their facility in Cary, North Carolina. The item at the center of this notice is CLEVIPREX, which is scientifically identified as clevidipine injectable emulsion. This is not a general over-the-counter supplement or a topical cream; it is a prescription-only (Rx Only) medication administered intravenously, typically used in hospital or clinical settings to manage high blood pressure. The specific formulation involved in this recall consists of 50 mg/100 mL (0.5 mg/mL) concentrations contained within single-use vials. Each case includes ten of these individual vials, designed for immediate clinical use rather than long-term home storage.
The manufacturing details are precise and critical for identifying the affected stock. While Chiesi USA, Inc. is the brand holder located in Cary, NC 27518, the actual production of this injectable emulsion was carried out by Fresenius Kabi in Graz, Austria. This international manufacturing chain means that healthcare providers across the country must look closely at the origin and lot numbers on their inventory. The National Drug Code (NDC) for this specific product is 10122-611-10. It is vital to distinguish this NDC from other strengths or packaging configurations of CLEVIPREX, as only the items matching this exact code are subject to the recall order.
The scope of the recall is limited to two specific lots of medication: lot number 1239521 and lot number 1237454. Both of these lots share an expiration date of October 2027. Despite having a future expiration date, which indicates the chemical stability of the drug itself may not be compromised by time, the recall was initiated on July 6, 2026. The distribution pattern covers the entire United States, meaning these vials could be in stock at hospitals, clinics, pharmacies, or healthcare facilities in any state. Because this is a Class II recall, it indicates a situation where use of the product might cause temporary or medically reversible serious injury, or the probability of serious injury is remote, but the lack of sterility assurance presents a significant enough risk to warrant immediate removal from the supply chain.
Understanding exactly what was recalled helps prevent confusion in busy medical environments. If you are a healthcare administrator or pharmacist reviewing inventory, do not rely solely on the brand name CLEVIPREX. You must verify the NDC 10122-611-10 and cross-reference it against the two specific lot numbers mentioned above. Any vials falling outside of lots 1239521 and 1237454 are not part of this recall action. Similarly, any product with a different expiration date or manufactured by a different facility is safe from this specific notice. The focus remains strictly on the ten-count single-use vials manufactured in Graz, Austria, for Chiesi USA, distributed nationwide as of early July 2026.
The hazard, explained
When the U.S. Food and Drug Administration (FDA) issues a Class II recall for CLEVIPREX (clevidipine injectable emulsion), the core concern revolves around the "Lack of Assurance of Sterility." To understand why this is a serious medical issue, it helps to look at what sterility actually means in a pharmaceutical context. A drug is considered sterile only when it is completely free of any living microorganisms, including bacteria, fungi, and viruses. Because CLEVIPREX is an injectable emulsion designed to go directly into the bloodstream, the manufacturer—Chiesi USA, Inc., manufacturing on behalf of Fresenius Kabi—must guarantee that the production environment and final packaging are entirely free from contamination. When a recall cites a lack of assurance, it does not necessarily mean that every single vial in the affected lots (specifically 1239521 and 1237454) is currently contaminated. Rather, it means that during the manufacturing process, there was a breach or uncertainty in the protocols that should have prevented contamination from occurring in the first place.
The physical mechanism of harm here is indirect but potentially severe. If a vial of this intravenous medication has been compromised by bacteria or other microbes during filling or sealing, those organisms can survive within the emulsion. When a patient receives an injection containing even a small number of these microorganisms, they are introduced directly into the systemic circulation. Unlike a topical cream where the skin acts as a barrier, intravenous drugs bypass the body’s primary defense systems. This direct entry allows any contaminants to multiply rapidly in the warm, nutrient-rich environment of the blood.
This scenario creates a high risk for serious infections such as sepsis (a life-threatening response to infection), bacteremia (bacteria in the blood), or localized abscesses at the injection site. For patients who are critically ill, elderly, or immunocompromised—populations that often require medications like clevidipine to manage acute blood pressure issues—the immune system may be too weakened to fight off these introduced invaders. The harm is not from the chemical composition of the drug itself, which remains chemically stable, but from the biological threat introduced by the failure in sterilization assurance. This is why the FDA classifies this as a Class II recall: while it is unlikely to cause serious adverse health consequences if used, the potential for infection is significant enough to warrant immediate correction and removal from the supply chain.
In general terms, injectable emulsions are particularly vulnerable to microbial growth because they often contain lipids (fats) that can serve as a food source for bacteria. Without rigorous environmental controls and validated sterilization processes during manufacturing, the risk of these organisms taking hold increases. The recall ensures that healthcare providers do not unknowingly administer a product where the safety barrier against these invisible threats has been compromised.
Who is most at risk
To understand who is truly at risk in this specific recall of Chiesi USA, Inc.’s CLEVIPREX (clevidipine injectable emulsion), it is essential to first clarify that this is not a product used in the home. CLEVIPREX is a prescription-only medication classified as an injectable emulsion designed for intravenous use in clinical settings. Therefore, the general public, including families with children or elderly individuals caring for relatives at home, are not directly exposed to this hazard through daily life activities. The risk is confined almost exclusively to patients currently receiving care in hospitals, intensive care units (ICUs), or emergency departments where Chiesi USA, Inc. distributed these specific vials nationwide.
The primary group at risk consists of patients who were administered CLEVIPREX 50 mg/100 mL (0.5 mg/mL) from Lot numbers 1239521 or 1237454, with an expiration date of October 2027, prior to the recall announcement on July 6, 2026. Because the hazard involves a "lack of assurance of sterility," the danger is not immediate toxicity but rather the potential presence of microbial contamination. For a typical healthy adult, a single exposure might result in no ill effects or a mild local reaction. However, for patients who are already critically ill, the stakes are significantly higher. These individuals often suffer from compromised immune systems due to underlying conditions such as cancer, organ failure, or severe trauma. In these cases, even a small amount of bacterial or fungal contamination introduced via an IV line can lead to serious systemic infections, including sepsis, which can be life-threatening.
Certain patient demographics are particularly vulnerable to the consequences of non-sterile injectables. Elderly patients, who frequently require blood pressure management during acute cardiac events, often have less robust immune responses and may struggle to fight off an infection that a younger person might clear easily. Similarly, patients with central venous catheters or other long-term intravenous access points are at elevated risk because these devices can provide a direct pathway for contaminants to enter the bloodstream, bypassing the body’s natural skin barriers. While the recall does not specify any incidents of injury to date, the potential for harm is greatest among those who are immunocompromised, critically hospitalized, or undergoing major surgical procedures where infection control is paramount.
It is also important to note that healthcare providers themselves are part of this risk equation. Nurses, pharmacists, and physicians handling these vials face a secondary risk of exposure if proper containment protocols fail during preparation or administration. Although the recall is driven by patient safety, the integrity of the supply chain matters for everyone involved in the clinical process. If you are a healthcare professional who may have used these specific lots, your institution’s pharmacy department should have already flagged this inventory. For patients, the key takeaway is that while you cannot check the lot number yourself at home, your medical team is responsible for verifying the safety of every drug administered to you during your stay.
How to tell if you have the recalled item
Identifying whether a specific medical product is part of this FDA recall requires careful attention to the details printed on the packaging and the vials themselves. Because CLEVIPREX (clevidipine injectable emulsion) is a prescription-only medication typically administered in clinical settings, you are most likely to encounter this product if you work in a hospital, clinic, or pharmacy, or if you are a healthcare provider managing patient inventory. For patients, it is crucial to understand that while you may not physically hold the box at home, verifying the lot numbers associated with your recent treatments is vital for safety.
The primary step in identification is locating the National Drug Code (NDC) and the Lot Number on the product label. You should look for the NDC 10122-611-10 printed clearly on the outer carton. This specific code identifies the exact configuration of the recalled item: a package containing 10 single-use vials of CLEVIPREX 50 mg/100 mL (which equals 0.5 mg/mL). It is important to note that this recall applies only to this specific package size and strength. Other concentrations or package quantities manufactured by Chiesi USA, Inc., or distributed under different NDCs, are not included in this specific action.
Next, examine the Lot Numbers printed on both the outer box and each individual vial. This recall affects two specific lots: 1239521 and 1237454. These numbers are critical because they distinguish the affected units from others that may look identical but were produced under different quality controls. If you see either of these lot numbers on your inventory, the items must be considered part of the recall immediately. Do not rely solely on the expiration date for identification, although it can serve as a secondary check. The recalled lots have an expiration date of 10/2027. However, because the issue relates to sterility assurance rather than chemical degradation, a product within its expiration window can still be unsafe if it bears one of the affected lot numbers.
You should also verify the manufacturer and distributor information. The product was manufactured for Chiesi USA, Inc., located in Cary, North Carolina 27518. However, the actual manufacturing took place by Fresenius Kabi in Graz, Austria. If you are inspecting a shipment or a stockroom, confirm that the origin matches these details. While the distribution pattern is nationwide within the United States, making it difficult to exclude items based on geography alone, the combination of the NDC, Lot Number, and manufacturer details will definitively identify whether a vial is part of this specific Class II recall.
If you are a patient who received CLEVIPREX recently, contact your healthcare provider or pharmacist with any records of your treatment dates. They can cross-reference the lot numbers used during your care against the recalled list. Never attempt to verify these details by looking at the drug’s appearance alone, as sterility issues cannot be detected by sight. The only way to know for sure is to match the printed codes exactly to the recall information provided by the FDA and Chiesi.
What to do — step by step
If you are a healthcare professional, pharmacist, or facility manager who currently has this specific lot of CLEVIPREX in your inventory, the first and most critical action is to immediately stop using these vials. Because the recall is driven by a "lack of assurance of sterility," continuing to administer this medication poses a significant risk of introducing harmful bacteria into a patient’s bloodstream. Even if the vial appears visually perfect—clear liquid with no particles—the internal contamination risk cannot be seen with the naked eye. Therefore, do not attempt to inspect the contents for quality before deciding to remove them from service. The moment you identify the product through the details below, it must be segregated from usable stock.
Once you have confirmed that you possess the affected units, you need to isolate them physically and electronically. Move the vials to a secure, clearly marked area in your pharmacy or storage room that is distinct from non-recalled medications. Label these boxes prominently with "DO NOT USE - RECALLED" to prevent any accidental administration by busy staff members who may not be aware of the specific recall details. Simultaneously, update your inventory management system to flag these items as unusable. This step is vital for patient safety, ensuring that no nurse or physician inadvertently selects a compromised vial during an emergency situation.
The next phase involves handling the physical product itself. You should not dispose of these vials in regular hospital waste streams, as they are still pharmaceutical products. Instead, contact Chiesi USA, Inc. directly for specific instructions on how to return or dispose of the units. According to the official FDA recall notice, the specific remedy details for this action were not fully stated in the provided text. However, standard protocol for Class II drug recalls involving sterility concerns typically requires either returning the product to the manufacturer for destruction or following strict hazardous waste disposal guidelines under the supervision of your facility’s compliance officer. Reach out to Chiesi USA, Inc. at their Cary, NC address (27518) or via their customer service channels to get explicit guidance on the return logistics.
If you are a patient who has been prescribed this medication, do not panic, but do act quickly. Contact your prescribing doctor or pharmacist immediately. Tell them you have been notified of the Chiesi USA recall for CLEVIPREX. They will help you determine if your specific prescription was filled with one of the affected lots (Lot #1239521 or Lot #1237454). If you have already received the medication but have not used it, do not take it. Hold onto the vial and the packaging so you can show the lot number to your healthcare provider. They will arrange for a replacement with a non-recalled batch or provide further instructions on disposal. Your health team is there to help you transition safely to a sterile alternative without interrupting your care plan.
Finally, document everything. Keep a record of when you identified the product, when you removed it from use, and who you spoke with regarding its return or replacement. This documentation is important for your facility’s quality assurance records and helps the FDA track the effectiveness of the recall. By following these steps methodically, you help ensure that no patient is exposed to a non-sterile injectable emulsion, maintaining the high standards of safety that the FDA requires.
Your refund, repair, or replacement options
When a medical product is pulled from the market due to safety concerns, the most immediate question for patients and healthcare providers is often, "What happens next?" In this specific recall involving Chiesi USA, Inc.’s CLEVIPREX (clevidipine injectable emulsion), the situation requires careful handling because the official recall facts provided do not explicitly state a standard remedy such as a refund, repair, or direct replacement program. This absence of stated terms is not an oversight on your part; it simply means that the public notice does not outline a consumer-facing return process in the same way a retail product recall might. Instead, the focus shifts entirely to clinical management and regulatory compliance, which is typical for Class II drug recalls involving prescription-only medications.
Because CLEVIPREX is a prescription medication administered in controlled medical settings, "refund" or "replacement" in the traditional consumer sense does not apply to individual patients holding unused bottles at home. You cannot simply mail this product back to Chiesi for a credit. The remedy here is defined by the actions of the healthcare system rather than a customer service portal. If you are a patient who received an infusion containing the affected lots (1239521 or 1237454), your medical team is responsible for monitoring your condition and ensuring continuity of care. They will determine if alternative treatments are necessary based on your specific health needs, not because of a voucher or coupon system tied to this recall.
For healthcare facilities, pharmacies, or distributors that may have these vials in stock, the "remedy" is strictly about inventory control and safe disposal. The lack of assurance of sterility means these products must be removed from use immediately to prevent potential infection risks. Facilities should not attempt to return the product for credit unless directed by specific regulatory guidance that has been issued directly to them, which is not detailed in this public summary. Instead, the standard procedure involves segregating the affected lot numbers and following FDA guidelines for the safe disposal of hazardous pharmaceuticals. This ensures that no compromised product enters the supply chain again.
If you are a patient concerned about whether you were exposed to this recalled drug, your first step is not to seek a refund but to contact your prescribing physician or pharmacist. They have access to detailed administration records and can verify if the specific lot numbers mentioned in this recall were used in your treatment. They will guide you on any necessary medical follow-up. Do not attempt to manage this situation through customer service channels intended for retail goods, as those lines are not equipped to handle prescription drug safety inquiries or regulatory compliance issues related to injectable emulsions.
- Contact your healthcare provider immediately if you suspect exposure to lots 1239521 or 1237454.
- Do not attempt to return the product for a refund; this is a clinical safety issue, not a retail transaction.
- Rely on medical professionals to manage any necessary treatment adjustments or monitoring.
What can happen if you ignore it
When a pharmaceutical product is recalled due to a lack of assurance of sterility, the stakes are fundamentally different from a labeling error or a minor packaging defect. You might be tempted to wait for a replacement, assuming that because the drug itself is chemically correct, the risk is negligible. However, ignoring this recall carries serious, potentially life-threatening consequences that extend far beyond a simple inconvenience. The core danger lies in the fact that CLEVIPREX is an injectable emulsion administered directly into the bloodstream or vein, bypassing the body’s natural first-line defenses.
Sterility in medical injections is not merely a regulatory formality; it is a critical safety barrier. When the assurance of sterility is compromised, there is a possibility that bacteria, fungi, or other microorganisms have contaminated the solution inside the vial. Because these contaminants are microscopic and invisible to the naked eye, you cannot tell if a specific vial is safe by looking at it, shaking it, or checking its expiration date. If you proceed with using a contaminated vial, you are effectively introducing pathogens directly into your circulatory system.
The immediate result of such exposure can be a severe systemic infection known as sepsis, or bacteremia if bacteria enter the blood. For patients who are already critically ill—often the very individuals requiring intensive care medications like clevidipine to manage blood pressure—their immune systems may already be compromised or overwhelmed. In these vulnerable states, even a small amount of bacterial contamination can trigger a rapid and aggressive immune response. This can lead to septic shock, a dangerous drop in blood pressure that can cause organ failure and death.
Beyond the immediate risk of acute infection, ignoring the recall means exposing yourself to the possibility of localized complications at the injection site, such as abscesses or phlebitis (inflammation of the vein). These conditions can delay recovery, require additional surgical interventions to drain infections, and prolong hospital stays. Furthermore, treating a secondary infection caused by contaminated medication often requires powerful antibiotics, which carry their own side effects and risks, including antibiotic resistance.
It is important to note that while the FDA recall notice for this specific lot does not currently list reported incidents or injuries, the absence of reported cases does not mean the risk is zero. Contamination events can be sporadic and unpredictable. Waiting for a warning sign before acting is a dangerous gamble with your health. The potential outcome of ignoring this recall is not just a minor complication; it is the introduction of a preventable, severe biological hazard into a medical treatment that was intended to help you. The risk is entirely avoidable through proper disposal and replacement, making inaction an unnecessary threat to your well-being.
Staying safe: broader tips
When it comes to prescription medications, particularly those administered via injection or intravenous infusion, the safety net relies heavily on a combination of professional oversight and personal vigilance. While manufacturers and regulatory bodies work tirelessly behind the scenes to ensure quality control, understanding how to protect yourself as a patient is an essential part of your healthcare journey. The recall of CLEVIPREX highlights a critical aspect of pharmaceutical safety: sterility. Because these drugs are injected directly into the bloodstream or administered in clinical settings where they bypass the body’s natural barriers, any compromise in sterility can lead to serious infections. Therefore, staying informed and proactive is your best defense against potential hazards that may slip through the cracks of large-scale production.
The most powerful tool you have as a consumer is reliable information. Regulatory agencies like the FDA issue recalls for various reasons, including manufacturing errors, labeling mistakes, or contamination risks. These updates are not meant to cause panic but to empower you with knowledge. Make it a habit to regularly check official government recall databases or sign up for email alerts from the FDA and your specific state’s health department. By doing so, you ensure that you are not relying on word-of-mouth or delayed news reports. If you have an active prescription or are currently undergoing treatment, verify the lot numbers of your medications against current recall notices. This simple step can prevent unnecessary anxiety if your product is safe, or prompt immediate action if it is not.
Beyond checking for recalls, maintain open lines of communication with your healthcare providers and pharmacists. They are your first line of defense in identifying potential issues. If you ever notice unusual changes in the appearance of a medication—such as cloudiness, discoloration, or particulate matter in a clear solution—do not hesitate to question it. In the case of injectable emulsions like CLEVIPREX, which are designed to be uniform and sterile, any deviation from the expected visual profile should be reported immediately. Pharmacists can also help you navigate distribution patterns; if a specific regional recall is announced, they can quickly check their inventory systems to see if your pharmacy was affected.
Finally, remember that safety is a shared responsibility between you and your care team. For home-use medications, always store them according to the manufacturer’s instructions to maintain their integrity until use. For hospital-administered drugs, trust that medical professionals follow strict sterile techniques, but also feel empowered to ask questions if something seems off during administration. By staying educated, monitoring official sources, and communicating clearly with your doctors, you take control of your health safety. This proactive approach not only protects you from specific recalled items but also builds a habit of mindfulness that serves you well throughout your entire healthcare experience.